DNA methylation in hepatocellular carcinoma

Tischoff, Iris; Tannapfel, Andrea; Demorrow, Sharon
March 2008
World Journal of Gastroenterology;3/21/2008, Vol. 14 Issue 11, p1741
Academic Journal
As for many other tumors, development of hepatocellular carcinoma (HCC) must be understood as a multistep process with accumulation of genetic and epigenetic alterations in regulatory genes, leading to activation of oncogenes and inactivation or loss of tumor suppressor genes (TSG). In the last decades, in addition to genetic alterations, epigenetic inactivation of (tumor suppressor) genes by promoter hypermethylation has been recognized as an important and alternative mechanism in tumorigenesis. In HCC, aberrant methylation of promoter sequences occurs not only in advanced tumors, it has been also observed in premalignant conditions just as chronic viral hepatitis B or C and cirrhotic liver. This review discusses the epigenetic alterations in hepatocellular carcinoma focusing DNA methylation.


Related Articles

  • Cancer epigenetics. Momparler, Richard L // Oncogene;9/29/2003 Review, Vol. 22 Issue 42, p6479 

    Aberrant DNA methylation of the promoter region is a key mechanism for inactivation of genes that suppress tumorigenesis. Genes that are involved in every step of tumor formation can be silenced by this mechanism. Inhibitors of DNA methylation, such as 5-azadeoxycytidine (5AZA), can reverse this...

  • Aberrant DNA methylation in hepatocellular carcinoma tumor suppression (Review). YOUHONG DONG; ANPING WANG // Oncology Letters;2014, Vol. 8 Issue 3, p963 

    Aberrant DNA methylation leads to altered gene expression, resulting in cancerous features. Numerous tumor suppressor genes are silenced by DNA methylation during hepatocarcinogenesis. Promoter CpG island hypermethylation is an important mechanism for inactivating tumor suppressor genes in...

  • Epigenetics provides a new generation of oncogenes and tumour-suppressor genes. Esteller, M. // British Journal of Cancer;1/30/2006, Vol. 94 Issue 2, p179 

    Cancer is nowadays recognised as a genetic and epigenetic disease. Much effort has been devoted in the last 30 years to the elucidation of the ‘classical’ oncogenes and tumour-suppressor genes involved in malignant cell transformation. However, since the acceptance that major...

  • Next-generation sequencing identified new oncogenes and tumor suppressor genes in human hepatic tumors. Amaddeo, Giuliana; Guichard, Cécile; Imbeaud, Sandrine; Zucman-Rossi, Jessica // OncoImmunology;Dec2012, Vol. 1 Issue 9, p1 

    Genetic studies were performed in a French series of hepatocellular carcinomas. New oncogenes (NFE2L2) and tumor suppressor genes (IRF2, ARID1A and RPS6K3) were found to be recurrently altered. Moreover, a genotoxic signature was identified, raising the possible implication of a genotoxic...

  • Suppression of the protein tyrosine phosphatase receptor type O gene (PTPRO) by methylation in hepatocellular carcinomas. Motiwala, Tasneem; Ghoshal, Kalpana; Das, Anindita; Majumder, Sarmila; Weichenhan, Dieter; Wu, Yue-Zhong; Holman, Kristen; James, S Jill; Jacob, Samson T; Plass, Christoph // Oncogene;9/25/2003, Vol. 22 Issue 41, p6319 

    A diet lacking folic acid and choline and low in methionine (folate/methyl deficient diet, FMD diet) fed to rats is known to produce preneoplastic nodules (PNNs) after 36 weeks and hepatocellular carcinomas (tumors) after 54 weeks. FMD diet-induced tumors exhibit global hypomethylation and...

  • Epigenetic Therapy for Solid Tumors: Highlighting the Impact of Tumor Hypoxia. Ramachandran, Shaliny; Ient, Jonathan; Göttgens, Eva-Leonne; Krieg, Adam J.; Hammond, Ester M. // Genes;Dec2015, Vol. 6 Issue 4, p935 

    In the last few decades, epigenetics has emerged as an exciting new field in development and disease, with a more recent focus towards cancer. Epigenetics has classically referred to heritable patterns of gene expression, primarily mediated through DNA methylation patterns. More recently, it has...

  • Frequent epigenetic inactivation of the RASSF1A gene in hepatocellular carcinoma. Schagdarsurengin, Undraga; Wilkens, Ludwig; Steinemann, Doris; Flemming, Peer; Kreipe, Hans H; Pfeifer, Gerd P; Schlegelberger, Brigitte; Dammann, Reinhard // Oncogene;3/27/2003, Vol. 22 Issue 12, p1866 

    Aberrant promoter methylation is a fundamental mechanism of inactivation of tumor suppressor genes in cancer. The Ras association domain family 1A gene (RASSF1A) is frequently epigenetically silenced in several types of human solid tumors. In this study, we have investigated the expression and...

  • Role of RASSF1A promoter methylation in the pathogenesis of hepatocellular carcinoma: a meta-analysis of 21 cohort studies. Li, Yong-Shuang; Xie, Qiang; Yang, Da-Ye; Zheng, Yuan // Molecular Biology Reports;Jun2014, Vol. 41 Issue 6, p3925 

    We carried out the current meta-analysis aiming to comprehensively assess the potential role of RASSF1A aberrant promoter methylation in the pathogenesis of hepatocellular carcinoma (HCC). A range of electronic databases were searched: Web of Science (1945-2013), the Cochrane Library Database...

  • Methylation Profiles Reveal Distinct Subgroup of Hepatocellular Carcinoma Patients with Poor Prognosis. Mah, Way-Champ; Thurnherr, Thomas; Chow, Pierce K. H.; Chung, Alexander Y. F.; Ooi, London L. P. J.; Toh, Han Chong; Teh, Bin Tean; Saunthararajah, Yogen; Lee, Caroline G. L. // PLoS ONE;Aug2014, Vol. 9 Issue 8, p1 

    Hepatocellular Carcinoma (HCC) is one of the leading causes of cancer-associated mortality worldwide. However, the role of epigenetic changes such as aberrant DNA methylation in hepatocarcinogenesis remains largely unclear. In this study, we examined the methylation profiles of 59 HCC patients....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics